Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Integrin Beta-6 (IB6) Directed ADC

Geo Regions

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven. 

Please acknowledge that you understand this before proceeding.

Integrin Beta-6 (IB6) Directed ADC

PF-08052667 | B6N is an investigational compound. Its safety and efficacy have not been established.

Share to an HCP

Overview + Rationale

Rationale for Cancer Target1

  • Integrins are a family of membrane-associated proteins involved in cellular adhesion, motility, and cytokinesis
  • IB6 expression has been reported to be elevated and with a consistent expression across bladder cancers, including non-muscle invasive bladder cancer (NMIBC)

 

Overview1

  • PF-08052667 is an investigational antibody-drug conjugate (ADC) composed of an anti-integrin beta-6 (IB6) antibody conjugated via a glucuronide linker to 8 molecules of monomethyl auristatin E (MMAE)
  • PF-08052667 has shown activity in vitro, ex vivo, and in vivo in bladder models spanning a range of antigen expression levels
  • PF-08052667 is designed to be delivered by intravesical instillation with a surfactant prewash to enhance tissue penetration

 

Mechanism of Action

Stage of Development

GU

High-risk non-muscle invasive bladder cancer (NMIBC)

Phase 1 Monotherapy and Combination
This information is current as of February 27th 2026.

References: 1. Dekker, J.D. et al. Annals of Oncology, Volume 36; 2. NCT07206225. https://clinicaltrials.gov/study/NCT07206225 Updated December 16, 2026.  Accessed January 20, 2026.